RecruitingPhase 1NCT03838926
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Sponsor
Vanda Pharmaceuticals
Enrollment
42 participants
Start Date
Sep 27, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Subject is ≥ 18 years at the time of signing informed consent;
- Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
- Presence of measurable or evaluable disease;
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
- Contraceptives or other approved avoidance of pregnancy measures
Exclusion Criteria6
- Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
- Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
- Undergone major surgery ≤ 2 weeks prior to starting study drug;
- Evidence of mucosal or internal bleeding;
- Impaired cardiac function or conduction defect;
- Concurrent severe and/or uncontrolled medical conditions
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTrichostatin A
Intravenous Infusion
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03838926